Botox Adds Therapeutic Indication For Idiopathic Overactive Bladder
This article was originally published in The Pink Sheet Daily
Executive Summary
The FDA approval for idiopathic OAB follows a narrower indication for OAB related to neurological diseases such as multiple sclerosis or spinal cord injury.
You may also be interested in...
Ocular And UroGen Team-Up With Drug-Makers On Drug-Delivery Hydrogels
Ocular Therapeutix will work with Regeneron to create a sustained-release formulation of aflibercept for the treatment of wet age-related macular degeneration and other serious retinal diseases. On the same day, UroGen announced plans to work with Allergan on a hydrogel for controlled release delivery of drugs to the bladder.
Deal Watch: Allergan, Regeneron Both Look To Hydrogel Tech
Most of the significant deal-making action during the past week took place in Asia as Piramal made a play to increase its injectables business, an Eisai affiliate out-licensed rights to ovarian cancer candidate farletuzumab, and EpimAb and Kymab agreed to collaborate on bispecific antibody therapeutics.
Allergan Bolsters Botox Business With Record-Setting Korean Deal
In the largest licensing deal ever signed by a Korean health care company, Medy-Tox teams up with Allergan for next-generation neurotoxin products that could help Allergan protect its lead as new competitors like J&J look to enter the market.